BRPI0923164A2 - formulações de imiquimod com concentração de dosagem menos e regimes de dosagem curtos para o tratamento de ceratose actínica. - Google Patents

formulações de imiquimod com concentração de dosagem menos e regimes de dosagem curtos para o tratamento de ceratose actínica.

Info

Publication number: BRPI0923164A2
Authority: BR; Brazil
Prior art keywords: treatment; short; actinic keratosis; imiquimod formulations; dosage
Prior art date: 2008-12-19

Application number

BRPI0923164A

Other languages

English (en)

Inventor

James H Kulp

James H Lee

Jason J Wu

Kodumudi S Balaji

Mchael T Nordsiek

Robert Babilon

Sharon F Levy

Tze-Chiang Meng

Valyn S Bahm

Original Assignee

Graceway Pharmaceuticals Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-12-19

Filing date

2009-12-11

Publication date

2016-01-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42316709&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0923164(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-12-11 Application filed by Graceway Pharmaceuticals Llc filed Critical Graceway Pharmaceuticals Llc

2016-01-26 Publication of BRPI0923164A2 publication Critical patent/BRPI0923164A2/pt

Links

208000009621 actinic keratosis Diseases 0.000 title 1
238000009472 formulation Methods 0.000 title 1
DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 title 1
229960002751 imiquimod Drugs 0.000 title 1
239000000203 mixture Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Dermatology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oil, Petroleum & Natural Gas (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Steroid Compounds (AREA)

BRPI0923164A 2008-12-19 2009-12-11 formulações de imiquimod com concentração de dosagem menos e regimes de dosagem curtos para o tratamento de ceratose actínica. BRPI0923164A2 (pt)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US13953608P	2008-12-19	2008-12-19
US14473109P	2009-01-14	2009-01-14
US20514509P	2009-01-15	2009-01-15
PCT/US2009/067759 WO2010080345A1 (en)	2008-12-19	2009-12-11	Lower dosage strength imiquimod formulations and short dosing regimens for treating actinic keratosis

Publications (1)

Publication Number	Publication Date
BRPI0923164A2 true BRPI0923164A2 (pt)	2016-01-26

Family

ID=42316709

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0923164A BRPI0923164A2 (pt)	2008-12-19	2009-12-11	formulações de imiquimod com concentração de dosagem menos e regimes de dosagem curtos para o tratamento de ceratose actínica.

Country Status (28)

Country	Link
US (13)	US20110021555A1 (pt)
EP (1)	EP2378876B1 (pt)
AR (1)	AR074802A1 (pt)
AU (1)	AU2009335943A1 (pt)
BR (1)	BRPI0923164A2 (pt)
CL (1)	CL2009002183A1 (pt)
CO (1)	CO6400171A2 (pt)
CR (1)	CR20110338A (pt)
CY (1)	CY1121485T1 (pt)
DK (1)	DK2378876T3 (pt)
DO (1)	DOP2011000195A (pt)
EA (1)	EA201100984A1 (pt)
ES (1)	ES2720149T3 (pt)
GE (1)	GEP20146198B (pt)
HR (1)	HRP20190306T1 (pt)
HU (1)	HUE041944T2 (pt)
IL (2)	IL213628A (pt)
LT (1)	LT2378876T (pt)
MX (2)	MX2011001555A (pt)
PA (1)	PA8855101A1 (pt)
PE (2)	PE20142367A1 (pt)
PL (1)	PL2378876T3 (pt)
PT (1)	PT2378876T (pt)
RS (1)	RS58566B1 (pt)
SI (1)	SI2378876T1 (pt)
SM (1)	SMT201900195T1 (pt)
TW (1)	TWI442923B (pt)
WO (1)	WO2010080345A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20100160368A1 (en) *	2008-08-18	2010-06-24	Gregory Jefferson J	Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
US20110030104A1 (en)	2008-08-29	2011-02-03	Los Alamos National Security, Llc	Nucleic acids encoding plant glutamine phenylpyruvate transaminase (GPT) and uses thereof
US20110030089A1 (en)	2008-08-29	2011-02-03	Los Alamos National Security, Llc	Transgenic plants with enhanced growth characteristics
WO2010080345A1 (en) *	2008-12-19	2010-07-15	Graceway Pharmaceuticals, Llc	Lower dosage strength imiquimod formulations and short dosing regimens for treating actinic keratosis
EA025993B1 (ru)	2009-07-13	2017-02-28	Медисис Фармасьютикал Корпорейшн	Композиции с более низким содержанием имиквимода и короткие режимы дозирования для лечения остроконечных и перианальных бородавок
DK2584900T3 (en) *	2010-06-25	2019-04-01	Medicis Pharmaceutical Corp	Combination therapy with cryosurgery and low-dose imiquimod for the treatment of actinic keratosis
US9072876B2 (en) *	2010-08-05	2015-07-07	Medicis Pharmaceutical Corporation	Pump systems and methods for storing and dispensing a plurality of precisely measured unit-doses of imiquimod cream
US9492682B2 (en) *	2011-09-14	2016-11-15	Medicis Pharmaceutical Corporation	Combination therapy with low dosage strength imiquimod and photodynamic therapy to treat actinic keratosis
ES2551614T3 (es) *	2011-11-30	2015-11-20	Merz Pharma Gmbh & Co. Kgaa	Uso de alcoholes pegilados para el tratamiento de la queratosis actínica
CA2871490C (en)	2012-04-27	2022-10-04	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Use of cpg oligonucleotides co-formulated with an antibiotic to accelerate wound healing
AU2014312086B2 (en)	2013-08-30	2020-03-12	Immunogen, Inc.	Antibodies and assays for detection of folate receptor 1
US9576445B2 (en)	2013-09-06	2017-02-21	Immersion Corp.	Systems and methods for generating haptic effects associated with an envelope in audio signals
US9711014B2 (en)	2013-09-06	2017-07-18	Immersion Corporation	Systems and methods for generating haptic effects associated with transitions in audio signals
US9619980B2 (en)	2013-09-06	2017-04-11	Immersion Corporation	Systems and methods for generating haptic effects associated with audio signals
IL298044B2 (en) *	2013-10-08	2024-11-01	Immunogen Inc	Dosing regimens of anti-FOLR1 immunoconjugate
WO2016040638A2 (en)	2014-09-10	2016-03-17	Washington University	Compositions and methods for treatment of pre-cancerous skin lesions
AU2016323968B2 (en)	2015-09-17	2023-07-06	Immunogen, Inc.	Therapeutic combinations comprising anti-FOLR1 immunoconjugates
WO2018165647A1 (en) *	2017-03-10	2018-09-13	Athenex, Inc.	Methods of treating and/or preventing actinic keratosis
CA3128973A1 (en)	2019-03-04	2020-09-10	Bhaskar Bhattacharyya	Data compression and communication using machine learning

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
USRE24906E (en)	1955-11-18	1960-12-13		Pressure-sensitive adhesive sheet material
US4722941A (en) *	1978-06-07	1988-02-02	Kali-Chemie Pharma Gmbh	Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4411893A (en) *	1981-08-14	1983-10-25	Minnesota Mining And Manufacturing Company	Topical medicament preparations
IL73534A (en) *	1983-11-18	1990-12-23	Riker Laboratories Inc	1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4751087A (en)	1985-04-19	1988-06-14	Riker Laboratories, Inc.	Transdermal nitroglycerin delivery system
US4746515A (en)	1987-02-26	1988-05-24	Alza Corporation	Skin permeation enhancer compositions using glycerol monolaurate
US5238944A (en)	1988-12-15	1993-08-24	Riker Laboratories, Inc.	Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
SE9601528D0 (sv) *	1996-04-23	1996-04-23	Pharmacia Ab	Transdermally administered dextromethorphan as antitissue agent
UA67760C2 (uk) *	1997-12-11	2004-07-15	Міннесота Майнінг Енд Мануфакчурінг Компані	Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
US20030007939A1 (en) *	1998-07-31	2003-01-09	Howard Murad	Pharmaceutical compositions and methods for managing dermatological conditions
US20020058674A1 (en) *	1999-01-08	2002-05-16	Hedenstrom John C.	Systems and methods for treating a mucosal surface
TR200101943T2 (tr)	1999-01-08	2002-04-22	3M Innovative Properties Company	Bir immun cevap modifayeri ile mukoza ile ilgili durumların tedavisine yönelik formülasyonlar ve metodlar.
US20030072814A1 (en) *	1999-12-16	2003-04-17	Maibach Howard I.	Topical pharmaceutical composition for the treatment of warts
US6894060B2 (en) *	2000-03-30	2005-05-17	3M Innovative Properties Company	Method for the treatment of dermal lesions caused by envenomation
US20020055517A1 (en) *	2000-09-15	2002-05-09	3M Innovative Properties Company	Methods for delaying recurrence of herpes virus symptoms
JP2005519849A (ja)	2001-06-15	2005-07-07	スリーエムイノベイティブプロパティズカンパニー	歯周病の治療用免疫応答調節剤
RU2327460C2 (ru) *	2001-11-29	2008-06-27	3М Инновейтив Пропертиз Компани	Фармацевтические составы, содержащие иммуномодулятор
US9668972B2 (en)	2002-10-25	2017-06-06	Foamix Pharmaceuticals Ltd.	Nonsteroidal immunomodulating kit and composition and uses thereof
US7893083B2 (en) *	2003-01-06	2011-02-22	Eugene Mandrea	Method of treating genital herpes
CA2518082C (en) *	2003-03-13	2013-02-12	3M Innovative Properties Company	Methods for diagnosing skin lesions
MXPA05009694A (es) *	2003-03-13	2005-10-20	3M Innovative Properties Co	Metodos para mejorar la calidad de la piel.
US20040192585A1 (en)	2003-03-25	2004-09-30	3M Innovative Properties Company	Treatment for basal cell carcinoma
US20040265351A1 (en) *	2003-04-10	2004-12-30	Miller Richard L.	Methods and compositions for enhancing immune response
US7521459B2 (en) *	2003-07-28	2009-04-21	Metabeauty Inc.	Method for treating damaged skin
US20090232755A1 (en) *	2003-07-28	2009-09-17	Leslie Baumann	Combination therapies for treating photodamaged skin
JP2007504172A (ja)	2003-09-02	2007-03-01	スリーエムイノベイティブプロパティズカンパニー	粘膜に関連した症状の処置に関する方法
AU2004312547A1 (en)	2003-12-31	2005-07-21	Taigen Biotechnology	Protease inhibitors
WO2005077411A2 (en) *	2004-02-10	2005-08-25	Innate Pharma	Composition and method for the treatment of carcinoma
US20080125485A1 (en) *	2004-02-17	2008-05-29	Action Medicines	Use of 2,5-Dihydroxybenzene Derivatives for Treating Actinic Keratosis
EP1735010A4 (en) *	2004-04-09	2008-08-27	3M Innovative Properties Co	METHODS, COMPOSITIONS AND PREPARATIONS FOR ADMINISTRATION OF IMMUNE RESPONSE MODIFIERS (MRI)
US20070196452A1 (en)	2004-06-07	2007-08-23	Jie Zhang	Flux-enabling compositions and methods for dermal delivery of drugs
CN1286529C (zh)	2004-06-11	2006-11-29	华中科技大学	具有皮肤靶向性的药物组合物及其制备方法和用途
US20060062755A1 (en) *	2004-09-21	2006-03-23	Woodward John R	Method of cancer screening; method of cancer treatment; and method of diabetes treatment
DE102004049223A1 (de) *	2004-10-08	2006-04-20	Johannes-Gutenberg-Universität Mainz	Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung
US20060105028A1 (en) *	2004-11-12	2006-05-18	Jie Zhang	Systems and methods for treating warts
US8080560B2 (en)	2004-12-17	2011-12-20	3M Innovative Properties Company	Immune response modifier formulations containing oleic acid and methods
WO2006084251A2 (en)	2005-02-04	2006-08-10	Coley Pharmaceutical Group, Inc.	Aqueous gel formulations containing immune reponse modifiers
AU2006286497A1 (en) *	2005-08-31	2007-03-08	Serentis Limited	Use of an aureolysin inhibitor for the treatment of inflammatory skin conditions characterised by colonisation with Staphylococcus aureus
WO2007032009A2 (en) *	2005-09-15	2007-03-22	Biomas Ltd.	Use of tellurium compounds for treatment of basal cell carcinoma and/or actinic keratosis
US8889154B2 (en)	2005-09-15	2014-11-18	Medicis Pharmaceutical Corporation	Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation
US20070081962A1 (en)	2005-10-06	2007-04-12	Amit Munshi	Novel delivery of immune response modifiers for removal of chronic tattoos
GB0524962D0 (en) *	2005-12-07	2006-01-18	Pharmakodex Ltd	Topical pharmaceutical compositions
US20070264317A1 (en) *	2006-05-15	2007-11-15	Perrigo Israel Pharmaceuticals Ltd.	Imiquimod cream formulation
US9023863B2 (en) *	2006-07-14	2015-05-05	Stiefel Research Australia Pty Ltd	Fatty acid pharmaceutical foam
US20100092401A1 (en)	2006-07-18	2010-04-15	Graceway Pharmaceuticals, Llc	Immune response modifier formulations
US8124096B2 (en)	2006-07-31	2012-02-28	3M Innovative Properties Company	Immune response modifier compositions and methods
PL2076260T3 (pl) *	2006-09-15	2011-08-31	Celgene Corp	Związki N-metyloaminometylo-izoindolu, kompozycje zawierające te związki, oraz metody ich stosowania
DK2428513T3 (en) *	2006-09-26	2017-08-21	Celgene Corp	5-substituted quinazolinone derivatives as anti-cancer agents
ES2607901T3 (es) *	2007-01-31	2017-04-04	Chongxi Yu	Profármacos hidrosolubles cargados positivamente de 1H-imidazo[4,5-c]quinolin-4-aminas y compuestos relacionados con ratas de penetración de piel muy altas
WO2008098232A1 (en) *	2007-02-08	2008-08-14	Graceway Pharmaceuticals, Llc	Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy
WO2008118881A1 (en)	2007-03-23	2008-10-02	Graceway Pharmaceuticals, Llc	Method and packages to enhance safety when using imiquimod to treat children diagnosed with skin disorders
WO2008118765A1 (en)	2007-03-23	2008-10-02	Graceway Pharmaceuticals, Llc	Methods and packages to enhance safety when using imiquimod to treat children diagnosed with skin disorders
WO2008140713A1 (en)	2007-05-08	2008-11-20	The Brigham And Women's Hospital, Inc	Methods and products for treating proliferative disorders
US8636982B2 (en) *	2007-08-07	2014-01-28	Foamix Ltd.	Wax foamable vehicle and pharmaceutical compositions thereof
GB0715428D0 (en)	2007-08-08	2007-09-19	Imp Innovations Ltd	Compositions and uses thereof
US20090130029A1 (en) *	2007-11-21	2009-05-21	Foamix Ltd.	Glycerol ethers vehicle and pharmaceutical compositions thereof
WO2009069006A2 (en) *	2007-11-30	2009-06-04	Foamix Ltd.	Foam containing benzoyl peroxide
MX2010007410A (es)	2008-01-15	2011-02-25	Dow Pharmaceutical Sciences	Formulacion de imiquimod.
EP2176408B9 (en)	2008-01-31	2015-11-11	Curevac GmbH	NUCLEIC ACIDS COMPRISING FORMULA (NuGiXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS
US20090246156A1 (en) *	2008-03-31	2009-10-01	Audrey Kunin	Anti-acne sunscreen composition
NZ588668A (en) *	2008-04-03	2013-01-25	Cognate 3	Uses of helicin and other glucopyranosyloxy benzaldehydes in the treatment of cancer
CA2722765C (en)	2008-04-28	2016-10-04	Novartis Ag	Nanoparticles for use in pharmaceutical compositions
US20110077297A1 (en)	2008-05-30	2011-03-31	Novelix Pharmaceuticals, Inc.	Compositions and methods for treatment of inflammation and hyperkeratotic lesions
MX379265B (es)	2008-06-26	2025-03-11	Anterios Inc	Aplicacion dérmica de toxina botulínica en nanoemulsiones para usarse en el tratamiento de trastornos de la piel.
US20100160368A1 (en)	2008-08-18	2010-06-24	Gregory Jefferson J	Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
US8343498B2 (en) *	2008-10-12	2013-01-01	Massachusetts Institute Of Technology	Adjuvant incorporation in immunonanotherapeutics
KR20110090892A (ko)	2008-10-31	2011-08-10	모베르그 데르마 아베	두 개 이상의 침투 증강제의 조합으로 구성되는 국소 조성물
WO2010080345A1 (en)	2008-12-19	2010-07-15	Graceway Pharmaceuticals, Llc	Lower dosage strength imiquimod formulations and short dosing regimens for treating actinic keratosis
WO2010088924A1 (en)	2009-02-06	2010-08-12	Telormedix Sa	Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
EA025993B1 (ru)	2009-07-13	2017-02-28	Медисис Фармасьютикал Корпорейшн	Композиции с более низким содержанием имиквимода и короткие режимы дозирования для лечения остроконечных и перианальных бородавок
US8476225B2 (en)	2009-12-04	2013-07-02	Gilead Sciences, Inc.	Antiviral compounds
US9072876B2 (en) *	2010-08-05	2015-07-07	Medicis Pharmaceutical Corporation	Pump systems and methods for storing and dispensing a plurality of precisely measured unit-doses of imiquimod cream
US9492682B2 (en) *	2011-09-14	2016-11-15	Medicis Pharmaceutical Corporation	Combination therapy with low dosage strength imiquimod and photodynamic therapy to treat actinic keratosis

2009
- 2009-12-11 WO PCT/US2009/067759 patent/WO2010080345A1/en not_active Ceased
- 2009-12-11 EA EA201100984A patent/EA201100984A1/ru unknown
- 2009-12-11 ES ES09837849T patent/ES2720149T3/es active Active
- 2009-12-11 SI SI200931933T patent/SI2378876T1/sl unknown
- 2009-12-11 US US12/636,613 patent/US20110021555A1/en not_active Abandoned
- 2009-12-11 EP EP09837849.0A patent/EP2378876B1/en active Active
- 2009-12-11 MX MX2011001555A patent/MX2011001555A/es active IP Right Grant
- 2009-12-11 PL PL09837849T patent/PL2378876T3/pl unknown
- 2009-12-11 HR HRP20190306TT patent/HRP20190306T1/hr unknown
- 2009-12-11 DK DK09837849.0T patent/DK2378876T3/en active
- 2009-12-11 GE GEAP200912310A patent/GEP20146198B/en unknown
- 2009-12-11 SM SM20190195T patent/SMT201900195T1/it unknown
- 2009-12-11 RS RS20190210A patent/RS58566B1/sr unknown
- 2009-12-11 LT LTEP09837849.0T patent/LT2378876T/lt unknown
- 2009-12-11 MX MX2015008994A patent/MX346455B/es unknown
- 2009-12-11 PT PT09837849T patent/PT2378876T/pt unknown
- 2009-12-11 AU AU2009335943A patent/AU2009335943A1/en not_active Abandoned
- 2009-12-11 HU HUE09837849A patent/HUE041944T2/hu unknown
- 2009-12-11 BR BRPI0923164A patent/BRPI0923164A2/pt not_active Application Discontinuation
- 2009-12-17 CL CL2009002183A patent/CL2009002183A1/es unknown
- 2009-12-17 TW TW098143460A patent/TWI442923B/zh active
- 2009-12-18 PE PE2014000347A patent/PE20142367A1/es not_active Application Discontinuation
- 2009-12-18 PE PE2009001323A patent/PE20100469A1/es not_active Application Discontinuation
- 2009-12-18 AR ARP090104978A patent/AR074802A1/es unknown
- 2009-12-18 PA PA20098855101A patent/PA8855101A1/es unknown
2011
- 2011-06-16 IL IL213628A patent/IL213628A/en active IP Right Grant
- 2011-06-17 CR CR20110338A patent/CR20110338A/es unknown
- 2011-06-17 DO DO2011000195A patent/DOP2011000195A/es unknown
- 2011-07-08 US US13/179,315 patent/US8222270B2/en active Active
- 2011-07-08 US US13/179,363 patent/US20110257217A1/en not_active Abandoned
- 2011-07-08 US US13/179,336 patent/US20110263633A1/en not_active Abandoned
- 2011-07-08 US US13/179,402 patent/US20110263634A1/en not_active Abandoned
- 2011-07-12 US US13/181,507 patent/US20110257219A1/en not_active Abandoned
- 2011-07-12 US US13/181,499 patent/US8236816B2/en active Active
- 2011-07-13 US US13/182,433 patent/US8299109B2/en active Active
- 2011-07-13 CO CO11087690A patent/CO6400171A2/es not_active Application Discontinuation
- 2011-07-17 US US13/184,556 patent/US20110263636A1/en not_active Abandoned
- 2011-07-18 US US13/184,579 patent/US20110263637A1/en not_active Abandoned
2012
- 2012-08-06 US US13/568,003 patent/US9370509B2/en active Active
2016
- 2016-06-20 US US15/187,751 patent/US10238644B2/en active Active
2017
- 2017-10-22 IL IL255163A patent/IL255163B/en active IP Right Grant
2019
- 2019-02-05 US US16/268,230 patent/US11318130B2/en active Active
- 2019-02-14 CY CY20191100200T patent/CY1121485T1/el unknown

Also Published As

Publication number	Publication date
IL255163A0 (en)	2017-12-31
US20110257217A1 (en)	2011-10-20
CY1121485T1 (el)	2020-05-29
CR20110338A (es)	2011-11-10
HRP20190306T1 (hr)	2019-05-03
GEP20146198B (en)	2014-11-25
US8299109B2 (en)	2012-10-30
DK2378876T3 (en)	2019-03-11
PA8855101A1 (es)	2010-07-27
US20110263634A1 (en)	2011-10-27
US20110021555A1 (en)	2011-01-27
US9370509B2 (en)	2016-06-21
SMT201900195T1 (it)	2019-05-10
US20200276182A1 (en)	2020-09-03
RS58566B1 (sr)	2019-05-31
ES2720149T3 (es)	2019-07-18
PL2378876T3 (pl)	2019-06-28
EP2378876A1 (en)	2011-10-26
US8236816B2 (en)	2012-08-07
AU2009335943A1 (en)	2013-10-24
US20110263636A1 (en)	2011-10-27
TW201040173A (en)	2010-11-16
CO6400171A2 (es)	2012-03-15
PE20100469A1 (es)	2010-07-31
US20110257219A1 (en)	2011-10-20
PT2378876T (pt)	2019-03-01
IL213628A (en)	2017-11-30
US20110257218A1 (en)	2011-10-20
SI2378876T1 (sl)	2019-05-31
EP2378876B1 (en)	2018-11-14
US20130210855A1 (en)	2013-08-15
AR074802A1 (es)	2011-02-16
EA201100984A1 (ru)	2012-01-30
US20110263635A1 (en)	2011-10-27
US20110257216A1 (en)	2011-10-20
WO2010080345A1 (en)	2010-07-15
CL2009002183A1 (es)	2011-01-07
PE20142367A1 (es)	2015-01-10
MX346455B (es)	2017-03-21
US10238644B2 (en)	2019-03-26
MX2011001555A (es)	2011-04-14
US20110263637A1 (en)	2011-10-27
US20110263633A1 (en)	2011-10-27
US11318130B2 (en)	2022-05-03
HUE041944T2 (hu)	2019-06-28
IL213628A0 (en)	2011-07-31
TWI442923B (zh)	2014-07-01
LT2378876T (lt)	2019-04-25
US8222270B2 (en)	2012-07-17
US20160303111A1 (en)	2016-10-20
EP2378876A4 (en)	2012-12-05
IL255163B (en)	2019-01-31
DOP2011000195A (es)	2011-12-15

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-04-24	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2018-05-15	B06I	Publication of requirement cancelled [chapter 6.9 patent gazette]
2018-06-05	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2018-10-23	B09B	Patent application refused [chapter 9.2 patent gazette]
2019-01-08	B09B	Patent application refused [chapter 9.2 patent gazette]	Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL

Publication	Publication Date	Title
BRPI0923164A2 (pt)	2016-01-26	formulações de imiquimod com concentração de dosagem menos e regimes de dosagem curtos para o tratamento de ceratose actínica.
CY2020043I1 (el)	2021-03-12	Παγιδες gdf για χρηση στη θεραπευτικη αντιμετωπιση της αναιμιας
EA201101117A1 (ru)	2012-03-30	Ингибиторы дпп-4 для лечения диабета у детей
BRPI0922233A2 (pt)	2018-05-29	compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas.
BR112012017150A2 (pt)	2017-10-10	formulação de anticorpo e regimes terapêuticos.
CY2016053I2 (el)	2017-06-28	Μεθοδοι αγωγης χρησιμοποιωντας φαρμακευτικες ουσιες συλληψης αμμωνιας
CY1120741T1 (el)	2019-12-11	Θεραπεια οζωδους σκληρυνσης
BRPI1013698A2 (pt)	2016-04-26	métodos para tratamento com o uso de terapia de combinação
CL2007003523A1 (es)	2008-08-22	Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad de pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso en el tratamiento profilactico o terapeutico del cancer
BRPI0807717A2 (pt)	2014-05-20	Inibidores de quinase úteis para o tratamento de doenças mieloproliferativas e outras doenças proliferativas.
PL2037902T3 (pl)	2013-12-31	Zastosowanie kanabidiolu w użyciu w leczeniu bólu neuropatycznego
BRPI1010739A2 (pt)	2016-03-15	formas de dosagens de apixaban.
CL2008001540A1 (es)	2009-05-22	Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2008001633A1 (es)	2008-12-12	Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
CL2012003026A1 (es)	2013-02-01	Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad.
PL2468290T3 (pl)	2015-08-31	Antagoniści aktywiny-ActRII do stosowania w leczeniu niedokrwistości
BRPI0909818A2 (pt)	2015-10-06	métodos, formas de dosagem e conjunto para administrar ziprasidona sem alimentos
CL2013001591A1 (es)	2013-12-27	Compuestos derivados de triazolopiridina; inhibidores de pde10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, entre otras enfermedades.
BRPI0910780A2 (pt)	2016-08-09	uso de antagonistas de opióides para o tratamento da retenção urinária
BRPI0913377A2 (pt)	2015-11-24	regime de dosagem
DK2310042T3 (da)	2013-03-04	Anvendelse af pasireotid til behandling af endogen hyperinsulinæmisk hypoglykæmi
BRPI0912687A2 (pt)	2016-01-26	uso de bactéria probiótica para o tratamento de hiperhomocisteinaemia
DK1928427T3 (da)	2010-03-08	Hidtil ukendt dosisformulering
UY32735A (es)	2011-02-28	Formulaciones de imiquimod de concentración de dosificación inferior y regímenes de dosificación cortos para tratar verrugas genitales y perianales.
EA201390287A1 (ru)	2013-07-30	Теобромин в комбинации с отхаркивающим или муколитическим средствами для применения в терапии